Collegium Pharmaceutical (COLL) Osake Kurssi

Collegium Pharmaceutical Inc is primarily active in the pharmaceutical industry.

The main competitors of Collegium Pharmaceutical Inc in the market are pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., and AstraZeneca.

Collegium Pharmaceutical Inc is a pharmaceutical company specializing in the development and commercialization of innovative prescription products for pain management. Founded in 2002, Collegium Pharmaceuticals has a strong history of delivering effective treatments for pain while striving to address the challenges associated with opioid misuse and abuse. The company focuses on utilizing its proprietary DETERx platform to develop abuse-deterrent medications for the treatment of various pain conditions. Collegium Pharmaceutical Inc aims to provide healthcare professionals and patients with safe and effective options for pain management, contributing to improved patient outcomes and reducing the risk of opioid abuse.

Collegium Pharmaceutical Inc has achieved several significant milestones. One notable achievement of the company was the FDA approval of its product Xtampza ER, an abuse-deterrent opioid medication for the management of severe pain. This approval showcases Collegium Pharmaceutical's dedication to developing innovative treatment options. Additionally, the company successfully launched Xtampza ER and established partnerships with reputable pharmaceutical companies for commercialization. Collegium Pharmaceutical Inc has also demonstrated continuous growth and expansion, reflecting its commitment to providing effective and safe medications to patients. Through its notable achievements, Collegium Pharmaceutical Inc has solidified its position as a leading player in the pharmaceutical industry.

Collegium Pharmaceutical Inc is primarily present in the United States.

Collegium Pharmaceutical Inc represents a set of values and a corporate philosophy that guide its operations. The company is committed to improving patients' lives by developing and delivering innovative and abuse-deterrent therapies. Collegium places great importance on innovation, patient focus, and responsibility to shareholders. With a strong dedication to research and development, Collegium aims to address unmet medical needs and enhance patient outcomes. By continuously striving for excellence, Collegium Pharmaceutical Inc aims to maintain its position as a leading provider of pharmaceutical solutions.

Analyytikot asettavat tällä hetkellä Collegium Pharmaceutical-osakkeelle keskimääräisen tavoitehinnan 47,50 USD (mediaani: 48,00 USD), mikä merkitsee +87,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 14 analyytikkoarvioon.

Collegium Pharmaceutical Analyytikkojen kursstavoitteet 2026

14 analyytikkoa arvioi tällä hetkellä Collegium Pharmaceutical-osaketta: 12 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Collegium Pharmaceutical-yhtiöltä 831,97 M USD liikevaihtoa ja 5,96 USD osakekohtaista tulosta.

Collegium Pharmaceutical Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Collegium Pharmaceutical-osake noteerataan hintaan 22,94 EUR (25,32 USD).

Collegium Pharmaceutical-osake (COLL) on listattuna 4 pörssissä, muun muassa: NASDAQ (COLL), Frankfurt (354.F), München (354.MU), Düsseldorf (354.DU).

Collegium Pharmaceutical Inc is an innovative company specialized in the development and marketing of medications for patients with pain and inflammation conditions. The company's business model is based on innovation and providing a differentiated product range to meet the needs of their target audience. The company offers a wide range of products, including opioid analgesics and narcotic antagonists. Collegium offers various branded medications such as Xtampza® ER, Nucynta® ER, and DETERx®, all of which have different effects on the body and are suitable for different pain conditions. The company's main focus is on research and development of new medications. Collegium dedicates significant financial resources to the research and development of pain treatment drugs. They have a variety of patented drugs in the development phase and are continuously striving to improve therapy options for pain patients. Additionally, Collegium invests in expanding its business model into new markets. The company has expanded its presence in international markets to reach a larger customer base and expand their business. Through partnerships with local companies, Collegium has increased its reach and global presence. Collegium also constantly strives to improve the efficiency and effectiveness of its business processes. The company invests in technology and automation to improve operational efficiency and enhance product quality. This also helps to identify cost savings in areas such as sales, procurement, and inventory management. Another important aspect of Collegium's business model is its partnership with service providers and distributors. The company works closely with pharmacies, medical facilities, and other healthcare organizations to sell its products and services. These partnerships bring additional sales and increase Collegium's visibility and credibility in the industry. Overall, Collegium offers a broad and esteemed portfolio of pain medications. The company follows an innovative business model based on strong innovation, partnerships, expansion into new markets, and a focus on efficient business processes. Collegium will continue to actively strive to maintain its position as a leading company in pain treatment and expand its business on a continuous basis.

odotettu liikevaihto Collegium Pharmaceutical on 831,97 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Collegium Pharmaceutical on 236,43 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Collegium Pharmaceutical:n hinta-voitto-suhde (P/E) on tällä hetkellä 4,25. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Collegium Pharmaceutical-osakkeen arvostusta.

Collegium Pharmaceutical:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,21. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Collegium Pharmaceutical-osakkeen arvostuskennuslukuna.

Collegium Pharmaceutical:n Eulpool-laatuscore on 6/10.

Collegium Pharmaceutical:n ISIN on US19459J1043. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Collegium Pharmaceutical:n WKN on A14SUV. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Collegium Pharmaceutical:n ticker on COLL. Tämä pörssinoteeraus käytetään Collegium Pharmaceutical-osakkeiden kauppaan pörssissä.